152 related articles for article (PubMed ID: 29684586)
1. Targeted biochemical profiling of brain from Huntington's disease patients reveals novel metabolic pathways of interest.
Graham SF; Pan X; Yilmaz A; Macias S; Robinson A; Mann D; Green BD
Biochim Biophys Acta Mol Basis Dis; 2018 Jul; 1864(7):2430-2437. PubMed ID: 29684586
[TBL] [Abstract][Full Text] [Related]
2. Metabolic signatures of Huntington's disease (HD): (1)H NMR analysis of the polar metabolome in post-mortem human brain.
Graham SF; Kumar PK; Bjorndahl T; Han B; Yilmaz A; Sherman E; Bahado-Singh RO; Wishart D; Mann D; Green BD
Biochim Biophys Acta; 2016 Sep; 1862(9):1675-84. PubMed ID: 27288730
[TBL] [Abstract][Full Text] [Related]
3. Brain urea increase is an early Huntington's disease pathogenic event observed in a prodromal transgenic sheep model and HD cases.
Handley RR; Reid SJ; Brauning R; Maclean P; Mears ER; Fourie I; Patassini S; Cooper GJS; Rudiger SR; McLaughlan CJ; Verma PJ; Gusella JF; MacDonald ME; Waldvogel HJ; Bawden CS; Faull RLM; Snell RG
Proc Natl Acad Sci U S A; 2017 Dec; 114(52):E11293-E11302. PubMed ID: 29229845
[TBL] [Abstract][Full Text] [Related]
4. Novel Metabolite Biomarkers of Huntington's Disease As Detected by High-Resolution Mass Spectrometry.
Graham SF; Kumar P; Bahado-Singh RO; Robinson A; Mann D; Green BD
J Proteome Res; 2016 May; 15(5):1592-601. PubMed ID: 27018767
[TBL] [Abstract][Full Text] [Related]
5. Energy defects in Huntington's disease: Why "in vivo" evidence matters.
Liot G; Valette J; Pépin J; Flament J; Brouillet E
Biochem Biophys Res Commun; 2017 Feb; 483(4):1084-1095. PubMed ID: 27639641
[TBL] [Abstract][Full Text] [Related]
6. Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain.
Lim NK; Hung LW; Pang TY; Mclean CA; Liddell JR; Hilton JB; Li QX; White AR; Hannan AJ; Crouch PJ
Hum Mol Genet; 2014 Aug; 23(15):4051-63. PubMed ID: 24634145
[TBL] [Abstract][Full Text] [Related]
7. Metabolite mapping reveals severe widespread perturbation of multiple metabolic processes in Huntington's disease human brain.
Patassini S; Begley P; Xu J; Church SJ; Reid SJ; Kim EH; Curtis MA; Dragunow M; Waldvogel HJ; Snell RG; Unwin RD; Faull RL; Cooper GJ
Biochim Biophys Acta; 2016 Sep; 1862(9):1650-62. PubMed ID: 27267344
[TBL] [Abstract][Full Text] [Related]
8. The RAGE receptor and its ligands are highly expressed in astrocytes in a grade-dependant manner in the striatum and subependymal layer in Huntington's disease.
Kim J; Waldvogel HJ; Faull RL; Curtis MA; Nicholson LF
J Neurochem; 2015 Sep; 134(5):927-42. PubMed ID: 26011179
[TBL] [Abstract][Full Text] [Related]
9. Mass Spectrometry Analysis of Wild-Type and Knock-in Q140/Q140 Huntington's Disease Mouse Brains Reveals Changes in Glycerophospholipids Including Alterations in Phosphatidic Acid and Lyso-Phosphatidic Acid.
Vodicka P; Mo S; Tousley A; Green KM; Sapp E; Iuliano M; Sadri-Vakili G; Shaffer SA; Aronin N; DiFiglia M; Kegel-Gleason KB
J Huntingtons Dis; 2015; 4(2):187-201. PubMed ID: 26397899
[TBL] [Abstract][Full Text] [Related]
10. Altered Aconitase 2 Activity in Huntington's Disease Peripheral Blood Cells and Mouse Model Striatum.
Chen CM; Wu YR; Chang KH
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29160844
[TBL] [Abstract][Full Text] [Related]
11. HdhQ111 Mice Exhibit Tissue Specific Metabolite Profiles that Include Striatal Lipid Accumulation.
Carroll JB; Deik A; Fossale E; Weston RM; Guide JR; Arjomand J; Kwak S; Clish CB; MacDonald ME
PLoS One; 2015; 10(8):e0134465. PubMed ID: 26295712
[TBL] [Abstract][Full Text] [Related]
12. Investigating the Transition of Pre-Symptomatic to Symptomatic Huntington's Disease Status Based on Omics Data.
Christodoulou CC; Zachariou M; Tomazou M; Karatzas E; Demetriou CA; Zamba-Papanicolaou E; Spyrou GM
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33049985
[TBL] [Abstract][Full Text] [Related]
13. Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease.
Nithianantharajah J; Hannan AJ
Neuroscience; 2013 Oct; 251():66-74. PubMed ID: 22633949
[TBL] [Abstract][Full Text] [Related]
14. Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease.
Swarnkar S; Chen Y; Pryor WM; Shahani N; Page DT; Subramaniam S
Neurobiol Dis; 2015 Oct; 82():66-77. PubMed ID: 26048156
[TBL] [Abstract][Full Text] [Related]
15. Manifestation of Huntington's disease pathology in human induced pluripotent stem cell-derived neurons.
Nekrasov ED; Vigont VA; Klyushnikov SA; Lebedeva OS; Vassina EM; Bogomazova AN; Chestkov IV; Semashko TA; Kiseleva E; Suldina LA; Bobrovsky PA; Zimina OA; Ryazantseva MA; Skopin AY; Illarioshkin SN; Kaznacheyeva EV; Lagarkova MA; Kiselev SL
Mol Neurodegener; 2016 Apr; 11():27. PubMed ID: 27080129
[TBL] [Abstract][Full Text] [Related]
16. Brain Cholesterol Synthesis and Metabolism is Progressively Disturbed in the R6/1 Mouse Model of Huntington's Disease: A Targeted GC-MS/MS Sterol Analysis.
Kreilaus F; Spiro AS; Hannan AJ; Garner B; Jenner AM
J Huntingtons Dis; 2015; 4(4):305-18. PubMed ID: 26639223
[TBL] [Abstract][Full Text] [Related]
17. Metabolism in Huntington's disease: a major contributor to pathology.
Singh A; Agrawal N
Metab Brain Dis; 2022 Aug; 37(6):1757-1771. PubMed ID: 34704220
[TBL] [Abstract][Full Text] [Related]
18. DNA microarray analysis of striatal gene expression in symptomatic transgenic Huntington's mice (R6/2) reveals neuroinflammation and insulin associations.
Crocker SF; Costain WJ; Robertson HA
Brain Res; 2006 May; 1088(1):176-86. PubMed ID: 16626669
[TBL] [Abstract][Full Text] [Related]
19. miR-10b-5p expression in Huntington's disease brain relates to age of onset and the extent of striatal involvement.
Hoss AG; Labadorf A; Latourelle JC; Kartha VK; Hadzi TC; Gusella JF; MacDonald ME; Chen JF; Akbarian S; Weng Z; Vonsattel JP; Myers RH
BMC Med Genomics; 2015 Mar; 8():10. PubMed ID: 25889241
[TBL] [Abstract][Full Text] [Related]
20. The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease.
Russell DS; Barret O; Jennings DL; Friedman JH; Tamagnan GD; Thomae D; Alagille D; Morley TJ; Papin C; Papapetropoulos S; Waterhouse RN; Seibyl JP; Marek KL
JAMA Neurol; 2014 Dec; 71(12):1520-8. PubMed ID: 25322077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
